Stifel Nicolaus Downgrades Vigil Neuroscience (NASDAQ:VIGL) to Hold

Stifel Nicolaus lowered shares of Vigil Neuroscience (NASDAQ:VIGL - Free Report) from a buy rating to a hold rating in a research note released on Wednesday morning, Marketbeat reports. The firm currently has $8.00 target price on the stock, down from their prior target price of $11.00.

Other equities analysts have also recently issued reports about the company. JMP Securities restated a "market perform" rating on shares of Vigil Neuroscience in a report on Thursday, May 22nd. Mizuho lowered Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 23rd. Guggenheim set a $8.00 target price on Vigil Neuroscience and gave the stock a "neutral" rating in a research report on Thursday, May 22nd. HC Wainwright lowered Vigil Neuroscience from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $14.00 to $8.00 in a research report on Tuesday. Finally, Citizens Jmp lowered Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Ten equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $10.80.

Vigil Neuroscience Price Performance

Shares of Vigil Neuroscience stock remained flat at $7.88 on Wednesday. The company's stock had a trading volume of 1,210,695 shares, compared to its average volume of 657,423. The firm has a market cap of $367.78 million, a P/E ratio of -3.83 and a beta of 1.90. Vigil Neuroscience has a 52-week low of $1.31 and a 52-week high of $7.95. The business has a 50 day moving average price of $2.79 and a 200-day moving average price of $2.45.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04. Sell-side analysts forecast that Vigil Neuroscience will post -2.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vigil Neuroscience

Large investors have recently made changes to their positions in the business. abrdn plc increased its position in shares of Vigil Neuroscience by 124.9% during the 4th quarter. abrdn plc now owns 528,472 shares of the company's stock valued at $898,000 after purchasing an additional 293,461 shares during the last quarter. Cubist Systematic Strategies LLC increased its position in shares of Vigil Neuroscience by 53.0% during the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after purchasing an additional 8,358 shares during the last quarter. Barclays PLC increased its position in shares of Vigil Neuroscience by 43.6% during the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after purchasing an additional 19,436 shares during the last quarter. Blair William & Co. IL purchased a new stake in shares of Vigil Neuroscience during the 4th quarter valued at $551,000. Finally, 683 Capital Management LLC increased its position in shares of Vigil Neuroscience by 14.8% during the 4th quarter. 683 Capital Management LLC now owns 1,400,000 shares of the company's stock valued at $2,380,000 after purchasing an additional 180,420 shares during the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.